

Applicant : Alnylam Pharmaceuticals, Inc.
Serial No. : To Be Assigned
Filed : Herewith
Page : 28 of 28

Attorney's Docket No.: 14174-070US1 / ALN014PC

REMARKS

The amendments to the specification update the cross-reference to related applications and insert a paper copy of the sequence listing. The general information in the sequence listing has been updated to reflect accurate information for the instant application.

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 CFR §§1.821 (f) and (g), respectively, are the same and contains no new matter.

Claims 2-17 and 25-40 are canceled by the above amendment. Claims 58 and 59 are amended to remove multiple dependencies, and new claim 60 is added by the amendment. Claims 1, 18-24, and 41-60 are presented for examination. No new matter has been added.

Applicants ask that all claims be examined in view of the amendment to the claims.

Please apply any other necessary charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 14174-070US1.

Respectfully submitted,

Date: October 17, 2005

Allyson R. Hatton
Allyson R. Hatton, Ph.D.
Reg. No. 54,154

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906